BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci174794 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Jun Watanabe und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Radiation Tolerance, Histones. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Diffuse midline glioma (DMG) H3K27-altered is one of the most malignant childhood cancers. Radiation therapy remains the only effective treatment yet provides a 5-year survival rate of only 1%. Several clinical trials have attempted to enhance radiation antitumor activity using radiosensitizing agents, although none have been successful. Given this, there is a critical need for identifying effective therapeutics to enhance radiation sensitivity for the treatment of DMG. Using high-throughput radiosensitivity screening, we identified bromo- and extraterminal domain (BET) protein inhibitors as potent radiosensitizers in DMG cells. Genetic and pharmacologic inhibition of BET bromodomain activity reduced DMG cell proliferation and enhanced radiation-induced DNA damage by inhibiting DNA repair pathways. RNA-Seq and the CUT&RUN (cleavage under targets and release using nuclease) analysis showed that BET bromodomain inhibitors regulated the expression of DNA repair genes mediated by H3K27 acetylation at enhancers. BET bromodomain inhibitors enhanced DMG radiation response in patient-derived xenografts as well as genetically engineered mouse models. Together, our results highlight BET bromodomain inhibitors as potential radiosensitizer and provide a rationale for developing combination therapy with radiation for the treatment of DMG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Division of Hematology, Oncology, Neuro-Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
- Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Neurological Surgery, Brain Research Institute, Niigata University, Niigata, Japan.
- Department of Molecular Biosciences.
- High Throughput Analysis Laboratory, and.
Förderung
- NCI NIH HHS
- NINDS NIH HHS
- National Institutes of Health
- Rally Foundation
- Pediatric Cancer Research Foundation
- Cure Starts Now Foundation
- Matthew Larson Foundation for Pediatric Brain Tumors
- Japan Society for the Promotion of Science
Zitieren
APA
Watanabe, J., Clutter, M. R., Gullette, M. J., Sasaki, T., Uchida, E., Kaur, S., Mo, Y., Abe, K., Ishi, Y., Takata, N., Natsumeda, M., Gadd, S., Zhang, Z., Becher, O. J., & Hashizume, R. (2024). BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma. Journal of Clinical Investigation. https://doi.org/10.1172/jci174794
Vancouver
Watanabe J, Clutter MR, Gullette MJ, Sasaki T, Uchida E, Kaur S, et al. BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma. Journal of Clinical Investigation. 2024. doi:10.1172/jci174794
BibTeX
@article{Watanabe2024,
author = {Watanabe, Jun and Clutter, Matthew R and Gullette, Michael J and Sasaki, Takahiro and Uchida, Eita and Kaur, Savneet and Mo, Yan and Abe, Kouki and Ishi, Yukitomo and Takata, Nozomu and Natsumeda, Manabu and Gadd, Samantha and Zhang, Zhiguo and Becher, Oren J and Hashizume, Rintaro},
title = {BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci174794}
}
EUVIMED